Fiztasovimab
Based on 1 Customer Validation
Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV.
For research use only. We do not sell to patients.
- Purity : 96.49%
- CAS No.: 2467411-25-0
- Molecular Weight:144.49 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-P99001
Human IgG1 kappa, Isotype ControlIgG1κ Isotype Control -
HY-N1127
TricinCMV Inhibitor -
HY-16305
MaribavirAnti-CMV Agent -
HY-15523
Braco-19Telomerase Inhibitor -
HY-109528
Fomivirsen sodiumCMV Inhibitor -
HY-A0032A
Valganciclovir hydrochlorideAntiviral Agent -
HY-15523A
Braco-19 trihydrochlorideTelomerase Inhibitor -
HY-16305R
Maribavir (Standard)Anti-CMV Agent -
HY-108261
TomeglovirCMV Inhibitor -
HY-100272
B220Antiviral Agent -
HY-A0032AR
Valganciclovir hydrochloride (Standard)Antiviral Agent -
HY-N1127R
Tricin (Standard)CMV Inhibitor
Biological Activity
Description
Isotype
Human IgG1 lambda2
Recommend Isotype Controls
Species Reactivity
Virus
IC50 & Target
HCMV
In Vitro
Fiztasovimab is isolated from Epstein-Barr virus-transformed peripheral B cells of a healthy donor[1].
Fiztasovimab has a broadly neutralizing activity against 4 laboratory strains (AD169, Towne, Davis, Merlin) and 42 Japanese clinical isolates, which included GCV-resistant isolates[1].
Fiztasovimab shows anti-hMCV activities in MRC-5 human embryonic fibroblast cells and human adult retinal pigment epithelial cells with IC50s of 13-105 ng/mL and IC90s of 0.208-1.026 μg/mL[1].
Fiztasovimab also inhibits cell-to-cell infection by hCMV isolates in adult retinal pigment epithelial cells with IC90s of 13-19 μg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
3077416 [NCBI]
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 lambda
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human cytomegalovirus (HCMV) Glycoprotein B/gB Protein can bind Fiztasovimab. The EC50 for this effect is 20.15 ng/mL.
Chemical Information
-
CAS No. 2467411-25-0
-
Appearance Liquid
-
Molecular Weight 144.49 kDa
-
Color Colorless to light yellow
-
SMILES
[Fiztasovimab]
-
Synonyms
NPC-21; EV2038
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Fiztasovimab Related Classifications
HY-P99621 Related Classifications
Powered by Bioz